0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > CD3 epsilon

CD3 epsilon

Brief Information

Name:T-cell surface glycoprotein CD3 epsilon chain
Target Synonym:T-cell surface antigen T3/Leu-4 epsilon chain,CD3-Epsilon
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CDE-H8224-SPR
 CD3 epsilon SPR

Bispecific T-cell Engager captured on Protein A Chip can bind Biotinylated Human CD3E, His Tag, primary amine labeling (Cat. No. CDE-H8224) with an affinity constant of 0.815 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

CDE-HR2H4-SPR
 CD3 epsilon SPR

Bispecific T-cell Engager captured on Protein A Chip can bind HRP-Human CD3 epsilon, His Tag (Cat. No. CDE-HR2H4) with an affinity constant of 4.45 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

FLJ18683,T3E,TCRE,CD3E,CD3-epsilon

Background

CD3e molecule, epsilon is also known as CD3E, is a T-cell surface single-pass type I membrane glycoprotein. CD3E contains 1 Ig-like (immunoglobulin-like) domain and 1 ITAM domain. CD3E, together with CD3-gamma, CD3-delta and CD3-zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, forms the T cell receptor-CD3 complex. This complex plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. The genes encoding the epsilon, gamma and delta polypeptides are located in the same cluster on chromosome 11. The epsilon polypeptide plays an essential role in T-cell development. CD3E plays an essential role in T-cell development, and defects in CD3E gene cause severe immunodeficiency. CD3E gene has also been linked to a susceptibility to type I diabetes in women. CD3E has been shown to interact with TOP2B, CD3EAP and NCK2.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Elranatamab RN-613; PF-06863135; PF‑3135 Approved Pfizer Inc Elrexfio, ELREXFIO, ELREXFIO™ United States Multiple Myeloma Pfizer Inc 2023-08-14 Bone Marrow Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma Details
Glofitamab RG-6026; RO-7082859; RG6026-2 Approved F. Hoffmann-La Roche Ltd COLUMVI, 高罗华 Canada Lymphoma, Large B-Cell, Diffuse F. Hoffmann-La Roche Ltd 2023-03-25 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma Details
Talquetamab JNJ-7564; JNJ-64407564 Approved Johnson & Johnson Innovative Medicine, Genmab A/S TALVEY United States Multiple Myeloma Janssen Biotech Inc 2023-08-09 Hematologic Neoplasms; Multiple Myeloma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Obrindatamab MGD-009; B7-H3 x CD3 Phase 2 Clinical Macrogenics Inc Mesothelioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Sarcoma; Neuroblastoma; Neurofibrosarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma Details
Emerfetamab AMG-673; AMG673 Phase 1 Clinical Amgen Inc Leukemia, Myeloid, Acute Details
Pacanalotamab AMG-420; BI-836909 Phase 1 Clinical Micromet Inc Multiple Myeloma Details
Gresonitamab AMG-910 Phase 1 Clinical Amgen Inc Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma Details
Eluvixtamab MT-114; AMG-330 Phase 1 Clinical Amgen Inc Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Etevritamab AMG-596 Phase 1 Clinical Amgen Inc Glioblastoma Details

This web search service is supported by Google Inc.

totop

Laisser un message